A B S T R A C T
Background. There is evidence that end-stage kidney disease patients who are older or with more comorbidity may have a poor trade-off between benefits of dialysis and potential harms. We aimed to develop a tool for predicting patient mortality in the early stages of receiving dialysis. Methods. In 23 658 patients aged 15þ years commencing dialysis between 2000 and 2009 in Australia and New Zealand a point score tool was developed to predict 6-month mortality based on a logistic regression analysis of factors available at dialysis initiation. Temporal validation used 2009-11 data from Australia and New Zealand. External validation used the UK Renal Registry.
Results. Within 6 months of commencing dialysis 6.1% of patients had died. A small group (4.7%) of patients had a high predicted mortality risk (>20%), as predicted by the point score tool. Predictive variables were: older age, underweight, chronic lung disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease (particularly for patients <60 years of age), late referral to nephrologist care and underlying cause of renal disease. The new point score tool outperformed existing models, and had an area under the receiver operating characteristic curve of 0.755 on temporal validation with acceptable calibration and 0.713 on external validation with poor calibration. Conclusion. Our point score tool for predicting 6-month mortality in patients at dialysis commencement has sufficient prognostic accuracy to use in Australia and New Zealand for prognosis and identification of high risk patients who may be given appropriate supportive care. Use in other countries requires further study.
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I N T R O D U C T I O N
Many patients with end-stage kidney disease are treated with renal replacement therapy (RRT), typically dialysis and, in suitable patients, kidney transplantation. While the decision to commence dialysis is often quite straightforward in young patients with little comorbidity, the changing demographics of patients initiating dialysis in the last decade have made the decision to commence RRT in an individual increasingly difficult and complex, involving quality of life considerations particularly in the elderly [1] [2] [3] . The mortality rate among patients receiving dialysis is non-linear over time [4] with a particularly high rate in the first year. Where the decision for dialysis commencement has already been made, a predictive early mortality tool could provide patients with individualized information regarding prognosis and also as an instrument for optimizing dialysis centre care by identifying high risk individuals.
Existing tools to predict risk for patients choosing dialysis possess limitations that prevent generalized application, such as for use in the elderly [5] , requiring laboratory results, developed on a small sample from a single centre [6, 7] requiring specialists' opinions, or specific to either peritoneal dialysis [8] or haemodialysis [9] . Limited tools exist for short time frames such as 6 months.
This study aimed to use data from patients in Australia and New Zealand to develop a new, easily understood and applied, valid prediction tool for all-cause mortality within 6 months of dialysis initiation for patients where the decision to receive dialysis has been made, based on variables available at the time of dialysis initiation. To address concerns that new prediction models are infrequently validated [10] , we also aimed to validate this tool, temporally in Australia and New Zealand and externally in UK dialysis patients [11] , and to compare the new tool's performance with existing models.
M A T E R I A L S A N D M E T H O D S

Registry of dialysis patients
The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) records data from all patients treated with RRT in Australia and New Zealand. Key data are collected when patients commence RRT and at regular surveys thereafter with extremely high data completeness achieved by restricting data collection to core clinical variables. All patients provide written informed consent for their data to be placed on the registry and used for research purposes. De-identified data were provided to researchers upon approval of this project by the ANZDATA steering committee. The UK Renal Registry, which collects individual patient data from all adult renal centres in the UK, was used for external validation.
Study design and outcome measurement
The ANZDATA registry data were used to derive and temporally validate a new prediction tool. The derivation cohort consisted of all patients who initiated dialysis between 1 January 2000 and 30 June 2009 and were at least 15 years of age at the time ( Figure 1 ). The temporal validation cohort consisted of all patients (age !15 years) who commenced dialysis between 1 July 2009 and 30 June 2011. To assess external validity we restricted the UK Renal Registry data to patients aged 18þ years commencing dialysis in the years 1999-2007.
We excluded a small number of patients who were lost to follow-up within 6 months of commencing dialysis. The study outcome was all-cause mortality at 6 months following commencement of dialysis.
Prognostic variables
Demographic characteristics, comorbidity status and kidney disease variables were collected at dialysis initiation. This information included patients ' 
Statistical analysis
A simple point score tool was based on the results of logistic regression using mortality status at 6 months after dialysis initiation as the outcome, and the main effects of 12 prognostic variables, without any variable selection algorithm being applied. The number of events observed in ANZDATA supported a model of this complexity [12] . Age was included as both a dichotomy (15-59 years or 60þ years), for subsequent consideration of interactions with other prognostic variables in terms amenable to clinical interpretation, and as a continuous variable. Exploratory analysis using fractional polynomial representations indicated that age possessed a reasonably linear association with the log-odds of mortality when adjusting for the other prognostic variables, and this was illustrated with an unadjusted locally weighted regression (lowess) smoothed plot.
To allow prognostic variables to have differing effects on mortality risk for subgroups of patients, interactions were considered between the variables and each of: diabetes as a comorbidity, age 60þ years, gender and race. Five interactions were identified as being of potential importance, reducing to one after using manual backwards selection among the interaction terms only, based on minimizing the Bayesian information criterion (BIC). Small reductions (<2) in BIC were ignored [13] .
The point scores were created following a common approach; multiplying by 4 those log odds-ratios of mortality greater in absolute value than 0.2 and rounding to the nearest integer (the coefficient for continuous age was rounded to one decimal place), which achieved a total potential point score range of approximately 0-30, with 30 representing the highest risk score [14] . Scores were categorized to identify subgroups at higher risks and patient characteristics summarized for these subgroups. The new point score tool was validated both temporally and externally.
Prediction performances of the newly developed Ivory point score tool, the model from Couchoud et al. [5] and Wagner et al.'s 'Model 2' [15] were summarized for discrimination ability using area under the receiver operating characteristic curve (AUC) and for calibration using a calibration curve, specifically the calibration intercept and slope, and the Hosmer-Lemeshow (H-L) statistic. The generalized discrimination performance of the AUC for the new Ivory tool was assessed in internal validation using a bootstrap technique [14] .
External prediction models were recalibrated to the mortality rate of new settings by fitting a logistic regression model to 6-month mortality with the model's predicted risk as the explanatory variable, thus estimating a new intercept and a single slope parameter. This recalibration affected calibration only and not the discrimination ability of a model.
All analyses were undertaken in Stata (StataCorp 2013; Stata Statistical Software: Release 13; StataCorp LP, College Station, TX, USA).
R E S U L T S
Patient characteristics
In total 23 658 patients were included in the derivation cohort ( Figure 1 ). Missing data for BMI or smoking status led to 111 patients (0.5%) being excluded from the model development. Patient characteristics are listed in Table 1 . Approximately 95% of patients had an estimated glomerular 
, i.e. stage 5 disease. The 6.1% of patients who died within 6 months of commencing dialysis were on average older than survivors and had a higher burden of comorbidities with the exception of diabetes mellitus Types 1 and 2. A greater proportion of those who died had been referred late for nephrology care. Older age was related to increased risk of 6-month mortality in an approximately linear way as illustrated in Figure 2 , when attention is focused on the typical patient age range (approximately 90% of patients were aged between 31 and 81 years at dialysis commencement).
Figure 2 also suggests possibly reduced risk at younger ages relative to the overall trend. Table 2 presents the coefficients and odds ratios of the 12 prognostic variables and one interaction used in the logistic regression model that underlies the new point score tool. Older age (per decade), late referral, underweight and presence of comorbidities all increased the risk of early death in dialysis patients. The impact of cerebrovascular disease on early mortality was more pronounced in younger patients than in older patients. In all, five interactions had been identified as being of potential importance in the initial modelling. The selection process retained only one of these: the interaction of age with cerebrovascular disease.
Outcome prediction
Ivory point score tool Table 3 shows the final result of converting coefficients in Table 2 to point scores, and presents scorings for seven hypothetical future patients. Increasing age and presence of comorbidities increased mortality risk, whereas smoking and race were not sufficiently strong predictors to warrant a point score.
As an example of the tool's application, a 40-year-old underweight patient with Type 1 DN, coronary artery disease, cerebrovascular disease and peripheral vascular disease has the same score as a 90 year old with DN (14.4 points). Table 4 summarizes the relationship between these point scores and the observed mortality risk. A score of 14-18 points, present in 24% of the cohort, was associated with a 12% risk of death within 6 months of commencement. The age at dialysis commencement in this high-risk group was broad Age at dialysis initiation, years FIGURE 2: Linearity of relationship between age at commencement of dialysis and mortality risk in the ensuing 6 months; illustration using unadjusted locally weighted regression (lowess) of proportions experiencing death by age with smoothing bandwidth for age axis of 0.2; age range 31 years (5th percentile) to 81 years (95th percentile) marked. <0.001 Baseline log-odds of 6-month mortality À6.000 n/a n/a n/a n/a
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[mean 72 years, standard deviation (SD) 8 years]. The highest point score category of >18 identified 4.7% of patients (mean age 77 years, SD 8 years) who had a high (20.5%) risk of death within 6 months of commencing dialysis. This highest risk group were mostly normal weight (56%), almost half had lung disease (44%), half had cerebrovascular disease (51%), and most had coronary heart disease (91%), peripheral vascular disease (63%) and late referral (83%). Table 5 summarizes the results of the Ivory point score tool performance and validation. The AUC for the Ivory tool was 0.751 and indicated reasonable discrimination ability. Calibration was not optimal (H-L statistic 21.9, P ¼ 0.005) although the small P-value perhaps reflects the large sample size more than poor calibration since there was no clear pattern of over-or under-estimation of mortality risk across the risk spectrum and the calibration curve indicated no bias in the calibration across that spectrum (Appendix 1, Figure A1 ). Internal validation calculated from 200 bootstrap resamples showed the over-optimism corrected AUC for the Ivory point score tool to be 0.751, similar to the observed AUC. This indicated reasonable discrimination ability.
Temporal validation
In ANZDATA, 5518 patients commenced dialysis between 1 July 2009 and 30 June 2011. Excluding patients following the same process in Figure 1 reduced this to 5284 patients. The new Ivory point score tool had an AUC of 0.755 (Table 5 ) with calibration being satisfactory when recalibrated (H-L statistic 6.6, P ¼ 0.58).
External validation with the UK Renal Registry
Due to BMI and late referral having extensive missing data in the UK Renal Registry, the Ivory point score tool could only partially be applied (n ¼ 32 664, after exclusion of 212 patients who were lost to follow-up within 6 months of dialysis start). Chronic obstructive pulmonary disease and heart disease were used in place of chronic lung disease and coronary artery disease, respectively. Renal vascular disease was reclassified as hypertensive nephropathy, and the three categories other, uncertain and pyelonephritis were reclassified as 'other'. Common ethnic groups in the UK registry such as South Asian and Black were included in the analysis, although the new Ivory tool does not distinguish these groups since they were uncommon in ANZDATA. The Ivory point scores had moderate discrimination in the UK Renal Registry (AUC ¼ 0.713) and, despite being recalibrated to that registry, showed evidence of miscalibration (Table 5) .
Performance of existing models
The Couchoud [5] prediction tool for 6-month mortality could only be implemented partially due to differences in information collected in ANZDATA. Dysrhythmia, active malignancy, severe behavioural disorder and total dependence for transfers were assumed absent for each patient. Further, information on underweight and diabetes as measured in ANZDATA were used, and coronary artery disease and peripheral vascular disease definitions from ANZDATA (known or suspected) were used in place of the Couchoud definitions (stage 3 or 4). Using this approach the Couchoud model had an AUC of 0.695 when applied to the temporal validation data. When applied to the subset of patients aged 75 years and older the Couchoud model had AUC ¼ 0.656, whereas the Ivory point score tool had AUC ¼ 0.688.
The Wagner [15] model had an AUC of 0.691 in the temporal validation dataset and AUC ¼ 0.725 in the UK Renal Registry dataset (from which its development occurred). In applying Wagner's model, information on dialysis modality at 3 months was omitted for closer comparison with the other models; results when including this information are shown in Table 5 .
D I S C U S S I O N
Using a large cohort of patients with end-stage kidney failure with complete coverage of dialysis units in Australia and New Zealand, we developed a new tool to predict 6-month mortality from dialysis initiation which compares favourably to existing tools that might be considered for the same task. The new Ivory tool has sufficient ability to discriminate between patients at lower and higher risk and can be used to: (i) provide prognosis for patients where dialysis has been decided upon and (ii) identify subgroups of patients at particularly high risk of early mortality for whom supportive care could be increased and awareness of the possible need to introduce end of life care could be discussed.
Prognosis
Our study was motivated by the desirability of identifying patient mortality risk with regards to dialysis [16, 17] , particularly within a 6-month period, and the absence of a prediction tool suitable for use by patients themselves and without restriction to a specific dialysis modality.
The prognostic variables we found, from among the available variables in ANZDATA, to confer the strongest increase to mortality risk were: older age, underweight, cerebrovascular disease (particularly among patients <60 years of age), coronary artery disease, chronic lung disease, peripheral vascular disease and late referral to nephrologist care. Underlying cause of renal disease was also associated with mortality.
Other assessments of short-term mortality after dialysis commencement broadly agree with our findings, although differing in exact comorbidities, and with occasional support for behavioural variables such as smoking to increase risk [4, 6, 7] . The Ivory point score tool omitted smoking due to its contradictory effect and weak contribution to prediction. Smoking may be a risk factor for later mortality rather than early mortality.
Risk prediction studies that include a physician's/specialist's subjective opinion of mortality risk are less comparable to our results due to the impact of adjusting for opinion. Cohen et al. [9] used laboratory and non-laboratory variables along with nephrologists' opinions, with similar findings to ours that diabetes was not strongly associated with mortality. Barrett et al. [7] found clinician's expectation of patients' mortality to be no better than a scoring system that was purely data driven.
Other studies have looked at short-to medium-term mortality prediction given survival to 90 days, or 6 months for example, and incorporate laboratory variables and dialysis modality information. Using data from AROii (second Analyzing Data, Recognizing Excellence and Optimizing Outcomes cohort), smoking and chronic kidney disease aetiology were found to be predictive of 2 year, but not 1 year, mortality along with similar prognostic variables to ours [18] . (over 70 years), cerebrovascular disease, peripheral vascular disease, along with left ventricular ejection fraction, albumin and urate. Another study found that models including a weighted simplified Charlson score could better predict longterm over short-term mortality [20] .
Wagner et al. [15] , studying 3-year mortality, also found predictors similar to ours: older age, White race, smoking status, diabetes as a cause of end-stage kidney disease, haemodialysis versus peritoneal dialysis treatment, and history of diabetes or cardiovascular disease, with an interaction such that cardiovascular disease was less predictive of mortality among patients with diabetes. A similar set of prognostic variables for longer-term mortality were determined by Plantinga et al. [21] as older age, comorbidity, smoking and decreased blood pressure. Hemke et al. [22] developed yearly mortality predictions spanning 10 years, using age, gender, primary renal disease and type of therapy at 90 days. However, in general these tools cannot be implemented at the time of preparing for dialysis commencement.
Comorbidity may be a more significant factor than age in patients >75 years of age enrolled in dialysis programs [23] . For older patients, our model's incorporation of the strong continuous relationship between age and mortality ( Figure 2 ) may explain the better fit of the Ivory model than the Couchoud [5] model to 75þ years patients, although the latter was disadvantaged by being applied externally and with compromised predictor information. We found some evidence of a differing (lessened) impact of comorbidities on mortality with age.
Identifying patient subgroups by risk of 6-month mortality
Commencing dialysis in patients >75 years old has been shown to improve survival compared with patients without dialysis, but with an attenuated advantage when comorbidity was considered [17] , and with possible negative impacts. With conservative care, patient quality of life and the number of hospital-free days may be the same or better than with dialysis [2, 3, 24, 25] . Patients and caregivers place importance on convenient treatment that improves survival and quality of life [26] .
The Ivory point score tool is for use after dialysis has been decided upon. The high risk patients that it identifies are able potentially to benefit from a higher degree of supportive care. The tool should not be used for the purpose of selecting patients for dialysis treatment. Nevertheless our findings suggest that age-based restrictions on dialysis may be inappropriate due to a continuous increase in 6-month mortality risk with age and also prognostic variables independent of age.
The Ivory tool would be reasonable to use for other clinical purposes such as the identification of a higher risk patient subgroup for a clinical trial.
Comparing dialysis centre performance
Comparing the outcomes of patients across different dialysis centres is a complex task but worthwhile if it identifies centres in which clinical systems could be improved to achieve optimal care. For assessment of 6-month mortality, the Ivory tool could be used, at least in Australia and New Zealand, as a standard tool to adjust for case-mix differences among centres or to indicate which variables must be adjusted for in the comparison of centre performance, although more research is required to assess its performance in doing so.
Limitations
Although many of the most important variables for prediction were available in ANZDATA, some potential predictors were unavailable, for example, laboratory variables at dialysis initiation, total dependence on others for patient transfer, severity of comorbidity and duration of smoking history. Enhanced prognostic variable information may improve the model's ability to discriminate. The generalizability of the model to other populations was only explored for UK patients, with limitations due to variable definitions and availability, and its generalizability may be impacted by differing population minority groups, which may vary in other parts of the world, along with differing healthcare systems, dialysis regimes and kidney transplant rates from those of Australia and New Zealand. We were unable to model the predicted risk of patients who decided not to commence dialysis, as data were not available for these patients.
Conclusion
The new Ivory point score tool achieves sufficient discrimination ability to be used for 6-month mortality prognosis and identification of patient subgroups at high risk, after the decision to commence dialysis has been made. The tool may be implemented online for patients or used as a means of shared communication between patient and clinician including as an indicator of the need for additional supportive care. 
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